Prostatype Genomics AB (publ) (PROGEN.ST)
SEK 1.85
(-1.86%)
SEK 1.85
(-1.86%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -18.09 Million SEK | -43.76% |
| 2022 | -25.09 Million SEK | -1100.08% |
| 2021 | 2.5 Million SEK | 117.67% |
| 2020 | -14.2 Million SEK | 0.0% |
| 2018 | 3.3 Million SEK | -31.41% |
| 2017 | 4.82 Million SEK | 16109.39% |
| 2016 | 29.75 Thousand SEK | 100.49% |
| 2015 | -6.05 Million SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -4.68 Million SEK | 0.0% |
| 2024 Q1 | -4.68 Million SEK | -20.26% |
| 2023 Q1 | -7.25 Million SEK | 1.9% |
| 2023 FY | -36.08 Million SEK | -43.76% |
| 2023 Q2 | -8.51 Million SEK | -17.36% |
| 2023 Q3 | -3.89 Million SEK | 54.28% |
| 2023 Q4 | -3.89 Million SEK | 0.0% |
| 2022 FY | -25.09 Million SEK | -1100.08% |
| 2022 Q4 | -7.39 Million SEK | -19.31% |
| 2022 Q3 | -6.2 Million SEK | 6.45% |
| 2022 Q2 | -6.63 Million SEK | -36.23% |
| 2022 Q1 | -4.86 Million SEK | -762.11% |
| 2021 Q1 | 799.91 Thousand SEK | 136.05% |
| 2021 FY | 2.5 Million SEK | 117.67% |
| 2021 Q4 | 735.02 Thousand SEK | -13.82% |
| 2021 Q3 | 852.88 Thousand SEK | 55.56% |
| 2021 Q2 | 548.26 Thousand SEK | -31.46% |
| 2020 FY | -14.2 Million SEK | 0.0% |
| 2020 Q4 | -2.21 Million SEK | -700.69% |
| 2020 Q3 | 369.39 Thousand SEK | -61.63% |
| 2020 Q2 | 962.75 Thousand SEK | 46.65% |
| 2020 Q1 | 656.5 Thousand SEK | 339.25% |
| 2019 Q4 | -274.39 Thousand SEK | 66.55% |
| 2019 Q3 | -820.42 Thousand SEK | 0.0% |
| 2018 FY | 3.3 Million SEK | -31.41% |
| 2017 FY | 4.82 Million SEK | 16109.39% |
| 2016 FY | 29.75 Thousand SEK | 100.49% |
| 2015 FY | -6.05 Million SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| AroCell AB (publ) | -2.1 Million SEK | -760.609% |
| Devyser Diagnostics AB (publ) | 148.1 Million SEK | 112.215% |
| Immunovia AB (publ) | -5.1 Million SEK | -254.22% |
| SenzaGen AB | 34.93 Million SEK | 151.786% |
| Spermosens AB | -169 Thousand SEK | -10604.142% |